Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study

BACKGROUND: Pertuzumab plus trastuzumab combined with chemotherapy has become a standard neoadjuvant therapy option for patients with high-risk human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). There is still not enough evidence for the efficacy and safety of neoadjuvant p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Meirong, Wang, Shouman, Wan, Nengbin, Yuan, Songlin, Hu, Xiongqiang, Zhou, Wei, Qing, Bohua, Liu, Mingwen, Sun, Weihua, Fan, Peizhi, Wang, Jianguo, Cao, Hong, Xu, Haifan, Dai, Bin, Tang, Peizhi, Qian, Liyuan, Zhao, Xi, Xiao, Jun, Zhou, Huaiying, Hu, Jinhui, Ding, Li, Tripodi, Domenico, Zdenkowski, Nicholas, O’Keefe, Thomas J., Sanchez, Alejandro Martin, Chen, Li, Zhang, Ping, Xu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843401/
https://www.ncbi.nlm.nih.gov/pubmed/36660637
http://dx.doi.org/10.21037/atm-22-6054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843401/
https://www.ncbi.nlm.nih.gov/pubmed/36660637
http://dx.doi.org/10.21037/atm-22-6054

Ejemplares similares